The PANDAI project will create a European Pandemics AI Observatory that will drastically enhance the ability of Europe to predict, prepare for, detect and respond to pandemics. The AI Observatory will integrate with the WHO European Observatory on Health Systems and Policies and provide epidemiologists, scientists, public health responders and policymakers with access to a powerful AI-driven analysis, forecasting and actionable recommendation toolset, trained on novel globally sourced data.

Cholera remains a severe diarrhoeal disease that can kill within hours if untreated. Despite being preventable and treatable, cholera continues to cause major public health crises, with over 730,000 cases and 5,000 deaths reported globally in 2024, the majority in sub-Saharan Africa. Climate change, extreme weather events, fragile healthcare systems and inadequate WASH infrastructure exacerbate the persistence of cholera and undermine existing control strategies. Although oral cholera vaccines have proven effective, global shortages and waning immunity highlight the urgent need for complementary interventions. HUNADIA addresses this gap by developing and clinically validating a novel oral antidiarrhoeal treatment (VR-AD-1005, “VR”) that directly neutralises cholera toxin-induced fluid loss, where rehydration and antibiotics fall short. Building on a successful Phase II trial in Bangladesh, which demonstrated an eightfold reduction in stool volume and halved hospitalisation times, HUNADIA will conduct a large-scale, adaptive Phase IIb/III, placebo-controlled trial across 7 high-burden SSA countries. The trial will generate robust evidence on safety, efficacy and clinical utility, including in vulnerable populations. Our multidisciplinary consortium unites 11 partners from Africa, Europe and Asia, spanning drug discovery, GMP manufacturing, late-stage clinical research, health economics and policy translation. By strengthening African clinical trial capacity, engaging with all stakeholder groups and integrating climate-health data, HUNADIA is uniquely positioned to deliver a scientifically sound, clinically effective, cost-efficient and socially accepted solution. By reducing cholera morbidity and mortality, alleviating the burden on health systems and enabling rapid outbreak response, HUNADIA will contribute directly to epidemic preparedness, affordable access to innovations, and the Global Task Force on Cholera Control’s 2030 elimination roadmap.

PUREMIND will deliver the first Integrated Mental Healthcare Ecosystem (IMHE) to predict/early identify Mental Health Disorders (MHD) and create more optimal personalised interventions to prevent MHD and thereby improving wellbeing in children, adolescents, and young adults (0–25 years). The ecosystem will mitigate key challenges associated with MHDs, specifically 1)Detection: 1 in 7 undetected and untreated MHD cases, 2)Efficiency of treatment: lack of tools and guidelines for personalised multidisciplinary interventions that work, 3)Access to Support and Care: long waiting times for care due to lack of trained personnel, 4)Inequality: disparate and inadequate inter- and intra-country mental healthcare services and 5)Modern Cultures and Lifestyle: the increasingly recognised risk factor of digital addiction resulting in sedentary, socially isolated lifestyle contributing to MHD. These will be addressed by PUREMIND’s approach of combining analytical modelling of dynamical systems in the cyber-physical context of a subject’s personal natural environment-gene-gut-brain-MHD interactions process creating a much-needed personalised intervention synthesis framework that will be exploited by an AI engine to deliver optimised personalised intervention, and a unique digital twin educating young people how MHD might develop depending on their environment and lifestyle. These 2 components will be combined in an accessible/ adaptable mobile app MyMind to measure at scale and allow a subject to seamlessly access a 4-tier service architecture involving family, community, clinical and emergency services, to support prediction/early detection of MHD, empowering them to monitor their own mental health at home/educational/community settings and taking preventive actions against MHD. The IMHE will be designed using Implementation Science approach and will be validated in a 12month pilot study in 7 European countries and 2 LMICs covering different socioeconomic and cultural scenarios.